Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 1167 Massachusetts Avenue ARLINGTON MA 02476 |
Tel: | 1-212-3621200 |
Website: | https://www.kalarx.com |
IR: | See website |
Key People | ||
Mark T. Iwicki Chairman of the Board, Chief Executive Officer | Todd M. Bazemore President, Chief Operating Officer | Mary Reumuth Chief Financial Officer, Treasurer |
Eric L. Trachtenberg Chief Compliance Officer, General Counsel, Corporate Secretary | Kim Brazzell Head of Research and Development, Chief Medical Officer | Darius Kharabi Chief Business Officer |
Business Overview |
KALA BIO, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research, development and commercialization of therapies for rare and severe diseases of the eye. The Company's biologics-based investigational therapies utilize its proprietary mesenchymal stem cell secretome (MSC-S) platform. The Company's product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived bio factors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its KPI-012 is used for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing. The Company is also engaged in the development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases. |
Financial Overview |
For the fiscal year ended 31 December 2023, KALA BIO Inc revenues decreased from $3.9M to $0K. Net loss decreased 6% to $42.2M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects General and administrative - Balancing decrease of 74% to $15.2M (expense), Interest income increase from $664K to $2.7M (income). |
Employees: | 43 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $2.48M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$39.36M as of Dec 31, 2023 |
Net annual income (TTM): | -$42.20M as of Dec 31, 2023 |
Free cash flow (TTM): | -$28.54M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 2,816,454 as of Mar 28, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |